The FDA-cleared BIOFIRE FILMARRAY PN Panel is a comprehensive diagnostic test that identifies 33 clinically relevant targets from sputum and bronchoalveolar lavage samples. For 15 bacteria, it provides semi-quantitative results, helping to differentiate between colonizing and pathogenic bacteria.
Bacteria (Semi-quantitative)
- Acinetobacter calcoaceticus-baumannii complex
- Enterobacter cloacae complex
- Escherichia coli
- Haemophilus influenzae
- Klebsiella aerogenes
- Klebsiella oxytoca
- Klebsiella pnewmoniae group
- Legionella pneumophila
- Moraxella catarrhalis
- Proteus spp.
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Stenotrophomonas maltophilia
- Streptococcus pneumoniae
- Streptococcus pyogenes
Atypical Bacteria (Qualitative)
- Chlamydia pneumoniae
- Legionella pneumophila
- Mycoplasma pneumoniae
Viruses
- Adenovirus
- Coronavirus
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza B
- Parainfluenza Virus
- Respiratory Syncytial Virus
Antimicrobial Resistance Genes
- Carbapenemases
- IMP
- KPC
- NDM
- OXA-48-like
- VIM
- ESBL
- CTX-M
- Methicillin Resistance
- mecA/C and MREJ (MRSA)
Technology: Multiplex PCR-based molecular diagnostics (syndromic approach)
Format: Single, self-contained, freeze-dried reagent pouch
Sample Type: Sputum and bronchoalveolar lavage (BAL) samples
Result Time: About an hour
Ease of Use: Automated workflow from sample to result, requiring minimal hands-on time
The PN Panel is a powerful tool for improving clinical outcomes in patients with pneumonia and other lower respiratory tract infections.1 By identifying a wide range of pathogens and providing semi-quantitative results, the panel helps clinicians make more-informed therapeutic decisions ensuring patients receive effective treatment.1 Its fast turnaround time is crucial for patient management, especially in critical care settings.
Related Systems
- Poole S., et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: results of a randomised controlled trial. Journal of Infection 2022. Dec;85(6):625-633. doi:10.1016/j.jinf.2022.09.003.
Contact Us
Eager to advance your biothreat detection and infectious disease diagnostic capabilities? Connect with us to discuss how BioFire can help strengthen your preparedness and accelerate your response in critical situations.